## depression

| **Descriptives** | **Overall**, N = 1391 | **Botswana**, N = 11 | **Burkina Faso**, N = 01 | **Egypt**, N = 131 | **Ethiopia**, N = 101 | **Ghana**, N = 21 | **Kenya**, N = 71 | **Mali**, N = 11 | **Morocco**, N = 11 | **Nigeria**, N = 201 | **South Africa**, N = 691 | **Sudan**, N = 11 | **Tanzania**, N = 01 | **Tunisia**, N = 31 | **Uganda**, N = 71 | **Zambia**, N = 01 | **Zimbabwe**, N = 41 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **tools** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *Center for Epidemiological Studies-Depression (CES-D)* | 15 (10.8%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 13 (18.8%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 2 (28.6%) | 0 (NA%) | 0 (0.0%) |
| *Edinburgh Postnatal Depression Scale (EPDS)* | 12 (8.6%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (28.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 10 (14.5%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Patient Health Questionnaire (PHQ-9)* | 11 (7.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 2 (20.0%) | 2 (100.0%) | 2 (28.6%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 3 (4.3%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (14.3%) | 0 (NA%) | 0 (0.0%) |
| *Beck Depression Inventory (BDI/BDI-II)* | 8 (5.8%) | 0 (0.0%) | 0 (NA%) | 2 (15.4%) | 0 (0.0%) | 0 (0.0%) | 1 (14.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 5 (7.2%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Mini International Neuropsychiatric Interview (MINI)* | 7 (5.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 6 (8.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (14.3%) | 0 (NA%) | 0 (0.0%) |
| *General Health Questionnaire-28 (GHQ-28)* | 6 (4.3%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (10.0%) | 3 (4.3%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Hospital Anxiety and Depression Scale (HADS)* | 6 (4.3%) | 0 (0.0%) | 0 (NA%) | 2 (15.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 2 (66.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Composite International Diagnostic Interview (CIDI)* | 5 (3.6%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (25.0%) |
| *Depression Anxiety Stress Scale (DASS-21)* | 5 (3.6%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 2 (20.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (10.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV)* | 5 (3.6%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 1 (5.0%) | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Structured Clinical Interview for DSM-IV (SCID IV)* | 5 (3.6%) | 0 (0.0%) | 0 (NA%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 3 (4.3%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Calgary Depression Scale for Schizophrenia (CDSS)* | 4 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (5.8%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *General Health Questionnaire-12 (GHQ-12)* | 4 (2.9%) | 0 (0.0%) | 0 (NA%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 1 (14.3%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Hamilton Depression Rating Scale (HAM-D)* | 4 (2.9%) | 0 (0.0%) | 0 (NA%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid)* | 4 (2.9%) | 0 (0.0%) | 0 (NA%) | 2 (15.4%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Child Depression Inventory (CDI)* | 3 (2.2%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (4.3%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Hopkins Symptom Check List-25 (HSCL-25)* | 3 (2.2%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 2 (28.6%) | 0 (NA%) | 0 (0.0%) |
| *Symptom Checklist-90-R (SCL-90-R)* | 3 (2.2%) | 0 (0.0%) | 0 (NA%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Brief Psychiatric Rating Scale (BPRS)* | 2 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (25.0%) |
| *Brief Psychiatric Rating Scale Expanded (BPRS-E)* | 2 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Child Depression Inventory – Short Form (CDI-SF)* | 2 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (14.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Geriatric Depression Scale (GDS)* | 2 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Montgomery Asberg Depression Rating Scale (MADRS)* | 2 (1.4%) | 0 (0.0%) | 0 (NA%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (25.0%) |
| *Patient Health Questionnaire (PHQ-2)* | 2 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Self Rating Depression Scale (SDS)* | 2 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *90 question Inventory developed by Shaheen and Rakhawy* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Beck Youth Inventories (BYI-II)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Child and Adolescent Symptom Inventory-5 (CASI-5)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (14.3%) | 0 (NA%) | 0 (0.0%) |
| *Choice Health Experience Questionnaire (CHEQ)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Clinical Diagnosis* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *four-dimensional symptom questionnaire (4DSQ)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *HIV/AIDS depression scale excluding items reflecting somatic symptoms* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *International Classification of Diseases (ICD-9)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)* | 1 (0.7%) | 1 (100.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Middlesex Hospital Questionnaire (MHQ)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Revised Clinical Interview Schedule (RCIS)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (25.0%) |
| *Schedule for Clinical Assessment in Neuropsychiatry (SCAN)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Structured Clinical Interview for DSM-5 (SCID-5)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Structured Diagnostic Interview for Axis I Disorders (SCID-I)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A)* | 1 (0.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (33.3%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| 1n (%) | | | | | | | | | | | | | | | | | |

## anxiety

| **Descriptives** | **Overall**, N = 701 | **Botswana**, N = 11 | **Burkina Faso**, N = 01 | **Egypt**, N = 111 | **Ethiopia**, N = 31 | **Ghana**, N = 01 | **Kenya**, N = 21 | **Mali**, N = 01 | **Morocco**, N = 11 | **Nigeria**, N = 201 | **South Africa**, N = 241 | **Sudan**, N = 01 | **Tanzania**, N = 01 | **Tunisia**, N = 41 | **Uganda**, N = 11 | **Zambia**, N = 01 | **Zimbabwe**, N = 31 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **tools** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *Depression Anxiety Stress Scale (DASS-21)* | 6 (8.6%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 2 (66.7%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 3 (15.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *General Health Questionnaire-28 (GHQ-28)* | 6 (8.6%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (33.3%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 2 (10.0%) | 3 (12.5%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Hospital Anxiety and Depression Scale (HADS)* | 6 (8.6%) | 0 (0.0%) | 0 (NA%) | 2 (18.2%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 2 (50.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Spielberger’s State-Trait Anxiety Inventory (STAI)* | 6 (8.6%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 4 (20.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 1 (25.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid)* | 4 (5.7%) | 0 (0.0%) | 0 (NA%) | 2 (18.2%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 2 (8.3%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Revised Children’s Manifest Anxiety Scale (RCMAS)* | 4 (5.7%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (50.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 3 (12.5%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *General Health Questionnaire-12 (GHQ-12)* | 3 (4.3%) | 0 (0.0%) | 0 (NA%) | 1 (9.1%) | 0 (0.0%) | 0 (NA%) | 1 (50.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Structured Clinical Interview for DSM-IV (SCID IV)* | 3 (4.3%) | 0 (0.0%) | 0 (NA%) | 1 (9.1%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (5.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Symptom Checklist-90-R (SCL-90-R)* | 3 (4.3%) | 0 (0.0%) | 0 (NA%) | 1 (9.1%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 2 (10.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Beck Anxiety Inventory (BAI)* | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (5.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Generalized Anxiety Disorder (GAD-7)* | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (5.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Hamilton Anxiety Rating Scale (HAM-A)* | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 1 (9.1%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Mini International Neuropsychiatric Interview (MINI)* | 2 (2.9%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 2 (8.3%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *90 question Inventory developed by Shaheen and Rakhawy* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 1 (9.1%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Beck Youth Inventories (BYI-II)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Brief Psychiatric Rating Scale (BPRS)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (33.3%) |
| *Child and Adolescent Symptom Inventory-5 (CASI-5)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 1 (100.0%) | 0 (NA%) | 0 (0.0%) |
| *Clinical Anxiety Rating Scale (CARS)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Composite International Diagnostic Interview (CIDI)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (33.3%) |
| *DSM-IV-TR criteria Axis I - III* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *four-dimensional symptom questionnaire (4DSQ)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Generalized Anxiety Disorder (GAD-2)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Hopkins Symptom Check List-25 (HSCL-25)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *International Classification of Diseases (ICD-9)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)* | 1 (1.4%) | 1 (100.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Middlesex Hospital Questionnaire (MHQ)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 1 (9.1%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Multidimensional Anxiety Scale for Children (MASC)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *mYPAS (modified Yale Anxiety Scale)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Revised Children’s Manifest Anxiety Scale* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Revised Clinical Interview Schedule (RCIS)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 1 (33.3%) |
| *Structured Clinical Interview for DSM-5 (SCID-5)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (4.2%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Taylor Manifest Anxiety Scale* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 1 (9.1%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 1 (25.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| *YPAS (Yale Anxiety Scale)* | 1 (1.4%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (0.0%) |
| 1n (%) | | | | | | | | | | | | | | | | | |

## psychosis

| **Descriptives** | **Overall**, N = 601 | **Botswana**, N = 11 | **Burkina Faso**, N = 11 | **Egypt**, N = 41 | **Ethiopia**, N = 121 | **Ghana**, N = 01 | **Kenya**, N = 01 | **Mali**, N = 01 | **Morocco**, N = 11 | **Nigeria**, N = 91 | **South Africa**, N = 191 | **Sudan**, N = 11 | **Tanzania**, N = 21 | **Tunisia**, N = 41 | **Uganda**, N = 31 | **Zambia**, N = 11 | **Zimbabwe**, N = 21 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **tools** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| *Positive and Negative Syndrome Scale (PANSS)* | 10 (16.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 1 (11.1%) | 8 (42.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) | 0 (0.0%) |
| *Brief Psychiatric Rating Scale (BPRS)* | 6 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 2 (22.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (75.0%) | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) |
| *Composite International Diagnostic Interview (CIDI)* | 6 (10.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (33.3%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) |
| *Diagnostic and Statistical Manual of Mental Disorders-4th Edition (DSM-IV)* | 5 (8.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (8.3%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 1 (100.0%) | 1 (11.1%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) |
| *Structured Clinical Interview for DSM-IV (SCID IV)* | 5 (8.3%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 4 (21.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Schedule for Clinical Assessment in Neuropsychiatry (SCAN)* | 4 (6.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (33.3%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *10th international classification of mental and behavioural disorders (ICD-10)* | 3 (5.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 1 (11.1%) | 1 (5.3%) | 0 (0.0%) | 1 (50.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Mini International Neuropsychiatric Interview (MINI)* | 3 (5.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 1 (11.1%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) | 0 (0.0%) |
| *Brief Psychiatric Rating Scale Expanded (BPRS-E)* | 2 (3.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (8.3%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Clinical Diagnosis* | 2 (3.3%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid)* | 2 (3.3%) | 0 (0.0%) | 0 (0.0%) | 2 (50.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Scale for the Assessment of Positive Symptoms (SAPS)* | 2 (3.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (8.3%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Brief Psychiatric Rating Scale for Children (BPRS-C)* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Diagnostic and Statistical Manual of Mental disorders 5th edition (DSM-5)* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) | 0 (0.0%) |
| *Five axis DSM IV clinical diagnosis* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)* | 1 (1.7%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Kiddie-Schedule for Affective Disorders and Schizophrenia − Present and Lifetime Version (K-SADS-PL)* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Patient version of Structured Clinical Interview for DSM-III-R (SCID-P)* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *SADS (Schedule for Affective Disorders and Schizophrenia)* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (50.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Scale for Assessment of Negative Symptoms (SANS)* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (8.3%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Schizophrenia Cognition Rating Scale (SCoRS)* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| *Structured clinical interview (Diagnostic Interview for Genetic Studies [DIGS])* | 1 (1.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0.0%) | 0 (0.0%) | 1 (5.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| 1n (%) | | | | | | | | | | | | | | | | | |